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INTRODUCTION
Papillary thyroid cancer (PTC) is the most common type of dif-
ferentiated thyroid carcinoma which accounts for at least 70% 
of all follicular-cell derived thyroid cancer, and its incidence has 
been increasing (1). Although the prognosis of PTC is generally 
good, up to 10% of patients would eventually die of the disease 
or face the morbidity of recurrence (2). Tumor staging, which is 
predictive of prognosis, is based on the size and extent of the 
primary tumor and the presence of lymph node or distant me-
tastasis (2). 
  The oncostatin M receptor (OSMR) gene, located 5p13.1, en-
codes a protein called OSMRβ which heterodimerizes with in-
terleukin (IL) 6 signal transducer (gp130) to form type II OSMR 
(3, 4). Once recruited, the receptor complexes allow the activa-
tion of Janus protein tyrosine kinase (JAK) and, subsequently, 
the activation of signal transducer and activator of transcription 
(STAT, mainly STAT3) and mitogen activated protein kinase 
(MAPK) (5-7). In melanoma or other solid tumors, the key role 
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of STAT3 is to mediate the growth inhibitory effect of OSM (8). 
  The OSM is a member of the IL6 family which is now consid-
ered a multifunctional cytokine that is implicated in the activa-
tion, proliferation and/or differentiation of several cell types, such 
as hepatocytes, osteoblasts and lung epithelial cells (7, 9, 10). 
OSM is more active than IL6 in inhibiting the proliferation of 
numerous solid tumor cell lines derived from breast or lung can-
cer, hepatoma, osteosarcoma and melanoma (9). In addition, it 
was reported to stimulate AIDS-related Kaposi’s sarcoma, my-
eloma, plasmacytoma, and human prostate cancer (11-14). OSM 
is a potent inhibitor of iodine metabolism and was show to de-
crease thyroid peroxidase mRNA levels in porcine thyroid cells 
(4). Iodide oxidation and coupling activities of thyroid peroxi-
dase are significantly lower in PTC than in diffuse goiter and 
benign adenoma (15). 
  Although OSM and its interaction with OSMR are related to 
PTC development and clinical characteristics, no genetic studies 
of this interaction between OSMR and PTC have been conduct-
ed. Thus, in the present study, we investigated whether single 
nucleotide polymorphisms (SNPs) of OSMR contribute to the 
development of PTC. Also, we assessed the association of SNPs 




Patients with PTC were recruited from the Kyung Hee Universi-
ty Hospital, Seoul, Korea. The PTC group included 85 patients 
(23 males and 62 females; mean of age, 53.2 years). A diagnosis 
of PTC and the presence of cervical regional lymph node me-
tastasis were both confirmed by pathologic examination. A total 
of 287 normal controls (156 males and 131 females; mean of 
age, 37.6 years) were included for comparison. None of the con-
trols were found to have any malignancy or thyroid disease at 
enrollment. Written informed consent was obtained from all in-
dividuals according to the Declaration of Helsinki guidelines. 
This study was approved by the Institutional Review Boards of 
the Medical Research Institute, Kyung Hee University Medical 
Center.
Patients’ profile and clinical data
To determine the association between the SNPs of OSMR and 
the clinicopathologic characteristics of PTC, patients were divid-
ed into subgroups according to size (≤1 cm vs. >1 cm), number 
(unifocality vs. multifocaltiy), bilaterality (unilateral vs. bilateral) 
of tumors, presence or absence of extrathyroidal invasion, lymph 
node metastasis and angiolymphatic invasion. The demographic 
characteristics of PTC patients and controls are shown in Table 1.
SNP selection and genotyping
The SNPs of the OSMR gene were selected using the database 
found at http://ncbi.nlm.nih.gov/SNP, dbSNP BUILD 131. Of the 
SNPs in the OSMR coding region, SNPs with low heterozygosity 
(below 0.1; rs16867807, rs35207712, rs35117676, rs35727755, 
rs34324145, rs35546805, rs2289925, rs2289926, rs35739767, 
rs3749737, and rs34080825), without Asian population 
(rs34675408), and without genotype information (rs10941412) 
were excluded. In the promoter region, SNPs with low hetero-
zygosity (below 0.1; rs76020575), a low minor allele frequency 
(below 0.05; rs540558), a mono genotype (rs5867434), and 
without genotype information (rs79913282, rs3763098, and 
rs13359039), were excluded. Finally, we selected the SNPs 
rs2278329 (missense, Asp553Asn) and rs2292016 (promoter, 
-100 G/T) and their heterozygosities were 0.226 and 0.242, re-
spectively. Blood samples for DNA extraction from each subject 
were collected in EDTA tube and then stored in a -80°C refrig-
erator. Genomic DNA was extracted using a QIAamp DNA 
mini kit (QIAGEN, Valencia, CA, USA). SNP genotyping was 
determined by direct sequencing. Genomic DNA was amplified 
using the following primers: rs2278329 (sense, 5′- CCACCCAA
GCACCTGTAACTAT-3′; antisense, 5′- CTAACACCCATGCTG-
GATTTGT-3′; 461 bp), rs2292016 (sense, 5′-GGACTTCTCTT-
GCCTGAAGATT-3′; antisense, 5′- AGGAATTCCCTCCCTTCA
GTC-3′; 347 bp). Polymerase chain reaction products were se-
quenced using an ABI Prism 3730XL analyzer (PE Applied Bio-
systems, Carlsbad, CA, USA). Sequence data were analyzed us-
ing SeqManII software (DNASTAR Inc., Madison, WI, USA).
Statistics
For all SNPs, Hardy-Weinberg equilibrium was assessed using 
SPNStats software (http://bioinfo.iconcologia.net/index.php? 
module=Snpstats). Helixtree (Golden Helix Inc., Bozeman, MT, 
USA) and SNPAnalyzer Pro (ISTECH Inc., Goyang, Korea) were 
used to analyze the genetic data. Multiple logistic regression 
models (codominant, dominant, and recessive) were performed, 
after adjustment for sex and age, for odds ratios (ORs), 95% 
confidence intervals (CIs), and corresponding P-values. Linkage 
disequilibrium (LD) block of polymorphisms was tested using 
Table 1. Clinicopathologic characteristics of the study population 




Tumor size >1 cm 40 (47)
Multifocal 30 (35)
Bilateral 26 (31)
Extrathyroidal invasion 43 (51)
Cervical lymph node metastasis 24 (28)
Angiolymphatic invasion 5 (6)
Values are presented as mean±SD or number (%).Hong IK et al.: OSMR Polymorphisms and Papillary Thyroid Cancer    195
Haploview version 4.2 (http://www.broadinstitute.org/haplo-
view/haploview). The online program AliBaba 2.1 (http://www.
gene-regulation.com/pub/programs/alibaba2) was used to deter-
mine whether SNPs affect transcription factors. The data were 
analyzed using SPSS ver. 18.0 (SPSS Inc., Chicago, IL, USA). 
For all statistical tests, the significance level was set at P<0.05.
RESULTS
Genotypic and allelic frequency of rs2278329 and rs2292016
The genotypic and allelic frequencies of rs2278329 and 
rs2292016 in PTC patients and controls are given in Table 2. The 
observed genotype distributions of the SNPs were in Hardy-
Weinberg equilibrium (P>0.05, data not shown). 
  No association between the genotype and allele frequencies 
of rs2278329 and rs2292016 were observed in the 85 PTC pa-
tients and 287 control subjects (Table 2). In the measurement of 
LD, no LD block was identified by the Gabriel method (16). 
Association between rs2278329 and rs2292016 and clinico-
pathologic characteristics
We analyzed the association of the OSMR gene polymorphisms 
with the clinicopathologic status of size (larger or smaller than 1 
cm), number (unifocality or multifocality), and bilaterality (uni-
lateral or bilateral) of tumors, and the presence or absence of 
lymph node metastasis, extrathyroidal invasion and lymphovas-
cular invasion. For rs2278329, we found a significant association 
between PTC and tumor size (dominant model, G/G vs. A/G 
and A/A; P=0.028; OR, 2.71; 95% CI, 1.12 to 6.57) (Table 3). 
The frequencies of the G/G, A/G, and A/A genotypes were 
68.9%, 28.9%, and 2.2% in sizes smaller than 1 cm, respective-
ly, and 45%, 45%, and 10% in sizes larger than 1 cm, respec-
tively. Additionally, there was a significant difference in the allele 
frequency: the A allele was higher in sizes large than 1 cm 
(32.5% vs. 16.7%; P=0.018; OR, 2.41; 95% CI, 1.17 to 4.98). 
Regarding the number of tumors, we found no significant asso-
ciation with genotypes: however, there was a significant differ-
ence in allele frequency: the A allele was higher in patients with 
the multifocaltiy (33.3% vs. 19.1%; P=0.040; OR, 2.12; 95% 
CI, 1.03 to 4.34) (Table 3). However, we found no significant as-
sociation with PTC in terms of bilaterality of tumors and pres-
ence of lymph node metastasis, extrathyroidal invasion and 
lymphovascular invasion. 
  We calculated the sample power to verify our data (http://
www.stat.ubc.ca/~rollin/stats/ssize/b2.html). In this study, the 
sample powers of each SNPs were 0.837 (rs2278329; number 
of cases for 80% power, 77) and 0.837 (rs2292016; number of 
cases for 80% power, 77), respectively. Accordingly, our results 
were acceptable.
  We attempted to determine whether the promoter SNP 
rs2292016 affects transcription factors using the online program 
AliBaba 2.1. The T-containing sequences can bind with ICSBF 
transcription factor, but IRF-I substitutes for ICSBF in G-con-
taining sequences. Assuming the change of transcript factor binds 
according to variants of SNP, this promoter SNP may affect the 
protein expression of OSMR.
DISCUSSION
We found no association between the SNPs rs2278329 (mis-
sense, Asp553Asn) and rs2292016 (promoter, -100 G/T) of the 
OSMR gene and PTC susceptibility. However, we found an as-
sociation between rs2278329 and clinicopathologic characteris-
tics, such as the size and number of tumors. 
  OSMR is a specific receptor OSM which is a member of the 
IL6 family (4). OSM, produced mainly by activated monocytes 
Table 2. Genotype and allele frequencies of oncostatin M receptor (OSMR) polymorphisms in patients with papillary thyroid cancer and in con-
trols
PTC  Control  Model OR (95% CI) P-value
rs2278329 Genotypes G/G 49 (57.6) 138 (48.2) Codominant1 1.64 (0.59−4.58) 0.342
missense A/G 31 (36.5) 117 (40.9) Codominant2 2.20 (0.81−5.98) 0.122
(Asp553Asn) A/A 5 (5.9) 31 (10.8) Dominant 1.95 (0.73-5.17) 0.182
Recessive 1.46 (0.90−2.38) 0.129
Alleles G 129 (75.9) 393 (68.7) 1.43 (0.97-2.12) 0.073
A 41 (24.1) 179 (31.3) 1
rs2292016 Genotypes G/G 48 (57.1) 126 (46.1) Codominant1 0.97 (0.41−2.34) 0.953
promoter T/G 28 (33.3) 115 (42.1) Codominant2 1.52 (0.66−3.54) 0.327
(-100 G/T) T/T 8 (9.5) 32 (11.7) Dominant 1.26 (0.56−2.85) 0.577
Recessive 1.56 (0.95−2.55) 0.079
Alleles G 124 (73.8) 367 (67.2) 1.38 (0.93 – 2.03) 0.108
T 44 (26.2) 179 (32.8) 1
P-values were from logistic regression analyses with the codominant1 (A/A vs. A/G), codominant2 (A/A vs. G/G), dominant, and recessive models control-
ling age and gender as covariates. Values are presented as number (%).
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and lymphocytes, is well recognized as a cytostatic cytokine for 
some types of tumor cell derived from melanoma (17), breast 
cancer (18), colorectal cancer (19), and glioma cells (20). In con-
trast, OSM stimulates the growth of AIDS-related Kaposi’s sar-
coma (12), myeloma (13), and plasmacytoma (14). It promotes 
the growth of DU145 human prostate cancer cells through the 
signaling of the OSM specific receptor (11). 
  IL6 was shown to be related to aggressive behavior in thyroid 
cancer (21). Thyroid tumor cells originating from undifferentiat-
ed carcinomas express cytokines such as IL6, leukemia inhibito-
ry factor, thyroid transcription factor-1, and paired box gene 8 
(22). OSM is a potent inhibitor of iodine metabolism in thyroid 
cells and is thought to be one of the principal cytokines that 
counter thyroid dysfunction under severe illness such as sepsis 
(4). In this study, we found the association between the tumor 
size and SNP rs2278329 of the OSMR gene. Tumor size is relat-
ed to the prognosis of PTC. Many studies have concluded that 
PTC ≤ 1 cm diameter has an excellent prognosis and very low 
mortality rate, even though debate has centered on the clinical 
significance of PTC ≤ 1 cm (23-26). We also found the associa-
tion between the multifocality and SNP rs2278329 of the OSMR 
gene. The relevance and importance of multifocality on progno-
sis are still obscure. According to Antonaci et al. (27), multifocal 
PTC showed aggressive biological biological and clinical features. 
In contrast, multifocality was not considered a prognostic deter-
minant for the categorization of tumors as low risk or high risk 
in the study of Hay et al. (28). Although the relevance of the 
multifocality is debated, it is associated with indications for 
completion of thyroidectomy after lobectomy and for postoper-
ative radioactive iodine ablation.
  A missense mutation was identified in the OSMR gene in three 
families of familial primary localized cutaneous amyloidosis 
(FPLCA) (3). FPLCA is an autosomal dominant disorder associ-
ated with chronic skin itching and deposition of epidermal kera-
Table 3. Subgroup analysis according to the clinicopathologic status of the SNP rs2278329 Asp553Asn in papillary thyroid cancer after adjust-
ment for sex and age
Genotype
Size of tumors
Model OR (95% CI) P-value
>1 cm (n=40) ≤1 cm (n=45)
Genotypes
G/G 18 (45.0) 31 (68.9) Codominant1 2.39 (0.95−5.98) 0.064
A/G 18 (45.0) 13 (28.9) Codominant2 6.89 (0.71−66.48) 0.095
A/A 4 (10.0) 1 (2.2) Dominant 2.71 (1.12−6.57) 0.028 
Recessive NA 0.183 
Alleles
G 54 (67.5) 75 (83.3) 1
A 26 (32.5) 15 (16.7) 2.41 (1.17-4.98) 0.018 
Number of tumors
Model OR (95% CI) P-value
Multiple (n=30) Single (n=55)
Genotypes
G/G 13 (43.3) 36 (65.5) Codominant1 2.28 (0.88-5.90) 0.089 
A/G 14 (46.7) 17 (30.9) Codominant2 4.15 (0.62−27.72) 0.141
A/A 3 (10) 2 (3.6) Dominant 2.48 (1.00−6.16) 0.051 
Recessive 2.94 (0.46-18.69) 0.252 
Alleles
G 40 (66.7) 89 (80.9) 1
A 20 (33.3) 21 (19.1) 2.12 (1.03-4.34) 0.040 
Bilaterality of tumors 
Model OR (95% CI) P-value
Bilateral (n=26) Unilateral (n=59)
Genotypes
G/G 12 (46.1) 37 (62.7) Codominant1 1.95 (0.74−5.15) 0.179 
A/G 12 (46.1) 19 (32.2) Codominant2 1.95 (0.74-5.15) 0.458 
A/A 2 (7.7) 3 (5.1) Dominant 1.96 (0.77-5.00) 0.157 
Recessive 1.56 (0.24-9.91) 0.640 
Alleles
G 36 (69.2) 93 (78.8) 1
A 16 (30.8) 25 (21.2) 1.65 (0.79-3.45) 0.181 
P-values were from logistic regression analyses with the codominant1 (G/G vs. A/G), codominant2 (G/G vs. A/A), dominant, and recessive models control-
ling age and gender as covariates. Values are presented as number (%).
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tin filament-associated amyloid material in the dermis (3). FPL-
CA keratinocytes showed reduced activation of the JAD/STAT, 
MAPK, and p13K/Akt pathways after stimulation with OSM or 
the cytokine IL31 stimulation. The 2 pathogenic amino acid sub-
stitutions, 2072T-C transition (Ile691Thr substitution) and 
1853G-C transversion (Gly618Ala) were located within the ex-
tracellular fibronectin type III like domains regions critical to re-
ceptor dimerization and function.
  The human SNP database (dbSNP BUILD131) presents fre-
quencies of genotype for rs2278329 (G/G:G/A:A/A; Chinese, 
0.533:0.333:0.133; Japanese, 0.600:0.378:0.022; Korean in this 
study, 0.482:0.409:0.108) and rs2292016 (G/G:G/T:T/T; Chi-
nese, 0.359:0.513:0.128; Japanese, 0.535:0.395:0.070; Korean 
in this study, 0.461:0.421:0.117). The allele frequencies of 
rs2278329 in the Korean population in this study (G, 0.687; A, 
0.313) were similar to those observed in Chinese (G, 0.700; A, 
0.300) and Japanese (G, 0.789; A, 0.211) populations. The allele 
frequencies of rs2292016 in the Korean population in this study 
(G, 0.672; T, 0.328) were also similar to those observed in Chi-
nese (G, 0.615; T, 0.385) and Japanese (G, 0.733; T, 0.267) pop-
ulations. 
  Our study has some limitations. First, sex ratio and mean age 
of controls differ in comparison with cases. However, the results 
from the large number of controls may overcome this problem. 
Second, the small number of patients may affect the statistical 
results, though the statistic power for analysis was reliable, so 
that a further study with large number of patients should be 
performed. 
  In conclusion, the OSMR polymorphism is associated with 
clinicopathologic characteristics of tumor growth and multifo-
caltiy development.
CONFLICT OF INTEREST
No potential conflict of interest relevant to this article was re-
ported. 
REFERENCES
1. Lang BH, Lo CY, Chan WF, Lam KY, Wan KY. Staging systems for 
papillary thyroid carcinoma: a review and comparison. Ann Surg. 
2007 Mar;245(3):366-78.
2. Lang BH, Lo CY, Chan WF, Lam KY, Wan KY. Prognostic factors in 
papillary and follicular thyroid carcinoma: their implications for 
cancer staging. Ann Surg Oncol. 2007 Feb;14(2):730-8.
3. Arita K, South AP, Hans-Filho G, Sakuma TH, Lai-Cheong J, Clem-
ents S, et al. Oncostatin M receptor-beta mutations underlie familial 
primary localized cutaneous amyloidosis. Am J Hum Genet. 2008 
Jan;82(1):73-80.
4. Isozaki O, Tsushima T, Miyakawa M, Emoto N, Demura H, Arai M, 
et al. Oncostatin M: a new potent inhibitor of iodine metabolism in-
hibits thyroid peroxidase gene expression but not DNA synthesis in 
porcine thyroid cells in culture. Thyroid. 1997 Feb;7(1):71-7.
5. Klausen P, Pedersen L, Jurlander J, Baumann H. Oncostatin M and 
interleukin 6 inhibit cell cycle progression by prevention of p27kip1 
degradation in HepG2 cells. Oncogene. 2000 Jul;19(32):3675-83.
6. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, 
Schaper F. Principles of interleukin (IL)-6-type cytokine signalling 
and its regulation. Biochem J. 2003 Aug;374(Pt 1):1-20.
7. Tanaka M, Miyajima A. Oncostatin M, a multifunctional cytokine. 
Rev Physiol Biochem Pharmacol. 2003 Jun;149:39-52.
8. Kortylewski M, Heinrich PC, Mackiewicz A, Schniertshauer U, 
Klingmuller U, Nakajima K, et al. Interleukin-6 and oncostatin M-
induced growth inhibition of human A375 melanoma cells is STAT-
dependent and involves upregulation of the cyclin-dependent ki-
nase inhibitor p27/Kip1. Oncogene. 1999 Jun;18(25):3742-53.
9. Grant SL, Begley CG. The oncostatin M signalling pathway: revers-
ing the neoplastic phenotype? Mol Med Today. 1999 Sep;5(9):406-
12.
10. Lacreusette A, Nguyen JM, Pandolfino MC, Khammari A, Dreno B, 
Jacques Y, et al. Loss of oncostatin M receptor [beta] in metastatic 
melanoma cells. Oncogene. 2006 Aug;26(6):881-92.
11. Mori S, Murakami-Mori K, Bonavida B. Oncostatin M (OM) pro-
motes the growth of DU 145 human prostate cancer cells, but not 
PC-3 or LNCaP, through the signaling of the OM specific receptor. 
Anticancer Res. 1999 Mar-Apr;19(2A):1011-5.
12. Miles SA, Martinez-Maza O, Rezai A, Magpantay L, Kishimoto T, 
Nakamura S, et al. Oncostatin M as a potent mitogen for AIDS-Ka-
posi’s sarcoma-derived cells. Science. 1992 Mar;255(5050):1432-4.
13. Zhang XG, Gu JJ, Lu ZY, Yasukawa K, Yancopoulos GD, Turner K, et 
al. Ciliary neurotropic factor, interleukin 11, leukemia inhibitory 
factor, and oncostatin M are growth factors for human myeloma cell 
lines using the interleukin 6 signal transducer gp130. J Exp Med. 
1994 Apr;179(4):1337-42.
14. Nishimoto N, Ogata A, Shima Y, Tani Y, Ogawa H, Nakagawa M, et 
al. Oncostatin M, leukemia inhibitory factor, and interleukin 6 in-
duce the proliferation of human plasmacytoma cells via the com-
mon signal transducer, gp130. J Exp Med. 1994 Apr;179(4):1343-7.
15. Takamatsu J, Hosoya T, Tsuji M, Yamada M, Murakami Y, Sakane S, 
et al. Peroxidase and coupling activities of thyroid peroxidase in be-
nign and malignant thyroid tumor tissues. Thyroid. 1992 Jan;2(3): 
193-6.
16. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel 
B, et al. The structure of haplotype blocks in the human genome. 
Science. 2002 Jun;296(5576):2225-9.
17. Brown TJ, Lioubin MN, Marquardt H. Purification and characteriza-
tion of cytostatic lymphokines produced by activated human T lym-
phocytes: synergistic antiproliferative activity of transforming growth 
factor beta 1, interferon-gamma, and oncostatin M for human mela-
noma cells. J Immunol. 1987 Nov;139(9):2977-83.
18. Liu J, Spence MJ, Wallace PM, Forcier K, Hellstrom I, Vestal RE. On-
costatin M-specific receptor mediates inhibition of breast cancer cell 
growth and down-regulation of the c-myc proto-oncogene. Cell 
Growth Differ. 1997 Jun;8(6):667-76.
19. Deng G, Kakar S, Okudiara K, Choi E, Sleisenger MH, Kim YS. 
Unique methylation pattern of oncostatin m receptor gene in can-
cers of colorectum and other digestive organs. Clin Cancer Res. 2009 
Mar;15(5):1519-26.
20. Halfter H, Lotfi R, Westermann R, Young P, Ringelstein EB, Stogbau-
er FT. Inhibition of growth and induction of differentiation of glioma 
cell lines by oncostatin M (OSM). Growth Factors. 1998 Mar;15(2): 
135-47.
21. Kurebayashi J, Otsuki T, Tanaka K, Yamamoto Y, Moriya T, Sonoo H. 
Medroxyprogesterone acetate decreases secretion of interleukin-6 
and parathyroid hormone-related protein in a new anaplastic thy-
roid cancer cell line, KTC-2. Thyroid. 2003 Mar;13(3):249-58.198    Clinical and Experimental Otorhinolaryngology   Vol. 4, No. 4: 193-198, December 2011
22. Lumachi F, Basso SM, Orlando R. Cytokines, thyroid diseases and 
thyroid cancer. Cytokine. 2010 Jun;50(3):229-33.
23. Lee J, Rhee Y, Lee S, Ahn CW, Cha BS, Kim KR, et al. Frequent, ag-
gressive behaviors of thyroid microcarcinomas in Korean patients. 
Endocr J. 2006 Oct;53(5):627-32.
24. Sugino K, Ito K Jr, Ozaki O, Mimura T, Iwasaki H, Ito K. Papillary 
microcarcinoma of the thyroid. J Endocrinol Invest. 1998 Jul-Aug; 
21(7):445-8.
25. Baudin E, Travagli JP, Ropers J, Mancusi F, Bruno-Bossio G, Caillou 
B, et al. Microcarcinoma of the thyroid gland: the Gustave-Roussy 
Institute experience. Cancer. 1998 Aug 1;83(3):553-9.
26. Besic N, Pilko G, Petric R, Hocevar M, Zgajnar J. Papillary thyroid 
microcarcinoma: prognostic factors and treatment. J Surg Oncol. 
2008 Mar 1;97(3):221-5.
27. Antonaci A, Anello A, Aucello A, Consorti F, Della Rocca C, Giovan-
none G, et al. Microcarcinoma and incidental carcinoma of the thy-
roid in a clinical series: clinical behaviour and surgical management. 
Clin Ter. 2006 May-Jun;157(3):225-9.
28. Hay ID, Thompson GB, Grant CS, Bergstralh EJ, Dvorak CE, Gor-
man CA, et al. Papillary thyroid carcinoma managed at the Mayo 
Clinic during six decades (1940-1999): temporal trends in initial 
therapy and long-term outcome in 2444 consecutively treated pa-
tients. World J Surg. 2002 Aug;26(8):879-85.